October 25th, 2019 – Adastra Labs Holdings Ltd. (“Adastra” or the “Company”) announces Chemia Analytics Inc. has been granted an Analytical Testing Licence by Health Canada under the Cannabis Act and Cannabis Regulations. “It’s been a long road, but we’re happy to be here,” said Andy Hale CEO of Adastra Labs Holdings Ltd. Last year on October 18th, Chemia Analytics Inc. was one of the first Analytical Testing licence applicants under the new CTLS that had been rolled out by Health Canada only the day before.
“This year has been a learning process for our team and now we have demonstrable proof that we can reach critical milestones,” stated Andy Hale. Following the completion of the licence application in CTLS, Chemia Analytics has completed the design of the lab space, nearly completed construction and selected equipment. Chemia Analytics forecasts the completion of construction by early November and operations commencing by the end of the year.
“We have been really pushing to lay a framework for success,” said future Head of Lab Priyanka Nalawade, ”following the selection of our analytical equipment, we spent considerable effort in the creation of a plan that will enable Chemia to rapidly and efficiently validate our methods. Every decision has been made to create the greatest possible benefit to our future clients and overarching operational goals.”
While Adastra Labs Inc. is still awaiting a Standard Processing licence, the future is looking bright. Adastra Labs Inc. QAP Donald Dinsmore elaborated, “having a Health Canada licenced Analytical Testing lab right next door is a tremendous benefit to Adastra. We expect routine in-process test results that will help us make informed decisions regarding the quality of our products. Real data, in real-time will help us put patients and customers first.”
For further information, please contact:
Andy Hale, CEO
About Adastra Labs Holdings Ltd.
In Canada, Adastra (through its wholly owned subsidiaries, Adastra Labs Inc. and Chemia Analytics Inc.) is in the application process to become a Standard Processor and Analytical Testing Laboratory under the Cannabis Act administered by Health Canada, with licences to produce cannabis extracts and provide third party analytical testing services. These licences will further enable Adastra and its subsidiaries to produce, package, sell (wholesale), and export medically focused and recreational cannabis extract and concentrate products in Canada to other licensed entities and internationally in jurisdictions where medical cannabis extraction products are legal.
The Company’s operations include a facility in British Columbia, Canada. The Company is developing its 13,035 square feet facility to be fully devoted to standard processing and laboratory testing by late 2019, from which it expects to produce significant amounts of cannabis oil and/or hemp oil for the Canadian wholesale medical and recreational markets.
The Company will offer a suite of unique products under several existing consumer-focused brands, including tinctures, medicinal oils, concentrates, and when legalized, gel capsules and vaporizer pens. Through acquisition of existing cannabis extraction brands and careful development of its new brands, Adastra will be positioned to be a leader in branded, commercialized products in both the medical and adult-use markets across North America and internationally.
CAUTIONARY NOTE REGARDING FORWARD-LOOKING INFORMATION: This news release contains “forward-looking information” and “forward-looking statements” (collectively, “forward-looking statements”) within the meaning of the applicable Canadian securities legislation. All statements, other than statements of historical fact, are forward-looking statements and are based on expectations, estimates and projections as at the date of this news release. Any statement that involves discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, assumptions, future events or performance (often but not always using phrases such as “expects”, or “does not expect”, “is expected”, “anticipates” or “does not anticipate”, “plans”, “budget”, “scheduled”, “forecasts”, “estimates”, “believes” or “intends” or variations of such words and phrases or stating that certain actions, events or results “may” or “could”, “would”, “might” or “will” be taken to occur or be achieved) are not statements of historical fact and may be forward-looking statements. In this news release, forward-looking statements relate, among other things, to: Adastra’s expectations concerning an increase in its production capacity. Forward-looking statements are necessarily based upon a number of estimates and assumptions that, while considered reasonable, are subject to known and unknown risks, uncertainties, and other factors which may cause the actual results and future events to differ materially from those expressed or implied by such forward-looking statements. Such factors include, but are not limited to general business, economic, competitive, political and social uncertainties. There can be no assurance that forward-looking statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Accordingly, readers should not place undue reliance on the forward-looking statements and information contained in this news release. Except as required by law, Adastra assumes no obligation to update the forward-looking statements of beliefs, opinions, projections, or other factors, should they change, except as required by law. SOURCE: Adastra Labs Holdings Ltd.